Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Form 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 10 09 2026] - (CGWL)FORM 8.3
- The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndromeThe U.S. FDA has granted Orphan Drug Designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of endogenous Cushing's syndrome Endogenous Cushing's Syndrome is a rare endocrine disorder driven in most cases by excess...
- Search JamClear Health Media Launches Four New iOS Clinical Assessment Apps and Updates Visual VerticalClear Health Media, an Australian developer of clinical software, today announced the release of four new iOS applications for clinical assessment, alongside a major update to its established Visual Vertical app."Many established clinical tests remain useful but are still administered using paper, stopwatches or specialised equipment," said Matthew Holmes of Clear Health Media. "Our aim is to use the capabilities already built into an...
- Persica Pharmaceuticals publishes new analysis of assay sensitivity in disc microbiology studies, reinforcing the potential for PP353 in vertebrogenic Lumbar Back PainLondon, UK, 11 September 2026 - Persica Pharmaceuticals Limited (“Persica”), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain (vLBP), today announced publication of a new analysis examining why previous disc microbiology studies have reported divergent findings on bacterial presence in spinal discs.
- Nicox annonce l’acceptation pour examen en Chine de la NDA de NCX 4701 La date PDUFA correspond à la date cible à laquelle la Food and Drug Administration (FDA) américaine prévoit d’achever la revue d’une demande d’autorisation de mise sur le marché (NDA) et de rendre sa décision, conformément au Prescription Durg User Fee Act (PDUFA).
- Nicox Announces NCX 470 NDA in China Accepted for Review1 A PDUFA date is the target date by which the U.S. Food and Drug Administration (FDA) aims to complete its review and issue a decision on a New Drug Application (NDA) under the Prescription Drug User Fee Act (PDUFA).
- Beta Bionics (NASDAQ: BBNX) Faces Securities Class Action Amid iLet FDA Compliance -- HBSSInvestors who lost money in BBNX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
- Avance Clinical Wins ANZCham's Australia-Taiwan Business Excellence Award in TaiwanAvance Clinical Taiwan has won the Australia-Taiwan Business Excellence Award at the 2026 Australia New Zealand Chamber of Commerce in Taiwan.
- Crown Care NEMT Launches Nationwide Private Pay Medical Transportation with Two-Hour Booking ConfirmationCrown Care NEMT Launches Nationwide Private Pay Medical Transportation with Two-Hour Booking Confirmation
- American Association of Kidney PatientsArkansas Kidney Champion Bob Abbott Enters Hall of FameLargest USA Kidney Group Hails Pine Bluff Hometown Hero Little Rock Hosts Kidney Patient Meeting on Science, — The American Association of Kidney Patients (AAKP), the nation's oldest and largest independent and nonpartisan kidney...
- The We Card Program, IncWe Card Awareness Month Spotlights Retailers' Role in Preventing Underage SalesDuring We Card Awareness Month this September, all retailers are encouraged to sharpen their employee training and reinforce compliance efforts as FDA enforcement of age-restricted product sales remains a critical focus. Now in its 31st year,...
- Big Pharma Setbacks Create a New Wave of Rebound PlaysThe biotech space is ripe with attractive rebound setups. $NVS, $NTHI, $TNON, $IRD, $LLY, $AMGN, and $BIAF